TTrialPathMatch Me to Trials
← Back to trials
RecruitingEndometrial Cancer

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Eligible age

18+ yrs

Accepts

Women

Locations

18 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (partial response) or disappears (complete response) after treatment. The safety of BNT323 will also be assessed by following the occurrence of unfavorable/adverse effects that are seen after treatment. Other measures include the pharmacokinetics of BNT323 (or how BNT323 moves through and out of the body), the body's immune response, and the impact on quality of life.

Sponsor: BioNTech SE

Where it's recruiting

California

Los Angeles

Colorado

Aurora

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Fort Lauderdale

Illinois

Peoria · Urbana

Kentucky

Lexington

Louisiana

Shreveport

Minnesota

Minneapolis

Nevada

Reno

New York

Mineola · New York · Syracuse

Ohio

Centerville · Hilliard

Source: ClinicalTrials.gov · NCT06340568 · last updated 2026-11-10

A Clinical Study of the Anti-cancer Effects of an Investigational Ther · TrialPath